Sanofi’s Q2CY23 result was boosted by solid traction in exports (up 30% YoY and ~25% of Q2 revenue), while domestic business took a back seat. Mandated price cuts of ~25% in Lantus (~25% of India sales) and other products under NLEM (15% of portfolio) may have dragged India growth by ~6% YoY, in our view.